BACKGROUND: Preprocedure clinical and pathologic factors have failed to consistently differentiate complete response (CR) from progressive disease (PD) in patients after isolated limb infusion (ILI) with melphalan for unresectable in-transit extremity melanoma. METHODS: Multiplex immunobead assay technology (Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel, Millipore Corp., Billerica, MA; and Magpix analytical test instrument, Luminex Corp., Austin, TX) was performed on pre-ILI plasma to determine concentrations of selected cytokines (MIP-1α, IL-1Rα, IP-10, IL-1β, IL-1α, MCP-1, IL-6, IL-17, EGF, IL-12p40, VEGF, GM-CSF, and MIP-1β) on a subset of patients (n = 180) who experienced CR (n = 23) or PD (n = 24) after ILI. Plasma from normal donors (n = 12) was also evaluated. RESULTS: Of 180 ILIs performed, 28 % (95 % confidence interval 22-35, n = 50) experienced a CR, 14 % (n = 25) experienced a partial response, 11 % (n = 21) had stable disease, 34 % (n = 61) had PD, and 13 % (n = 23) were not evaluable for response. Tumor characteristics and pharmacokinetics appeared similar between CR (n = 23) and PD (n = 24) patients who underwent cytokine analysis. Although there were no differences in cytokine levels between CR and PD patients, there were differences between the melanoma patients and controls. MIP-1α, IL-1Rα, IL-1β, IL-1α, IL-17, EGF, IL-12p40, VEGF, GM-CSF, and MIP-1β were significantly higher in normal controls compared to melanoma patients, while IP-10 was lower (p < 0.001) in controls compared to melanoma patients. CONCLUSIONS: Patients with unresectable in-transit melanoma appear to have markedly decreased levels of immune activating cytokines compared to normal healthy controls. This further supports a potential role for immune-targeted therapies and immune monitoring in patients with regionally advanced melanoma.
BACKGROUND: Preprocedure clinical and pathologic factors have failed to consistently differentiate complete response (CR) from progressive disease (PD) in patients after isolated limb infusion (ILI) with melphalan for unresectable in-transit extremity melanoma. METHODS: Multiplex immunobead assay technology (Milliplex MAP Human Cytokine/Chemokine Magnetic Bead Panel, Millipore Corp., Billerica, MA; and Magpix analytical test instrument, Luminex Corp., Austin, TX) was performed on pre-ILI plasma to determine concentrations of selected cytokines (MIP-1α, IL-1Rα, IP-10, IL-1β, IL-1α, MCP-1, IL-6, IL-17, EGF, IL-12p40, VEGF, GM-CSF, and MIP-1β) on a subset of patients (n = 180) who experienced CR (n = 23) or PD (n = 24) after ILI. Plasma from normal donors (n = 12) was also evaluated. RESULTS: Of 180 ILIs performed, 28 % (95 % confidence interval 22-35, n = 50) experienced a CR, 14 % (n = 25) experienced a partial response, 11 % (n = 21) had stable disease, 34 % (n = 61) had PD, and 13 % (n = 23) were not evaluable for response. Tumor characteristics and pharmacokinetics appeared similar between CR (n = 23) and PD (n = 24) patients who underwent cytokine analysis. Although there were no differences in cytokine levels between CR and PDpatients, there were differences between the melanomapatients and controls. MIP-1α, IL-1Rα, IL-1β, IL-1α, IL-17, EGF, IL-12p40, VEGF, GM-CSF, and MIP-1β were significantly higher in normal controls compared to melanomapatients, while IP-10 was lower (p < 0.001) in controls compared to melanomapatients. CONCLUSIONS:Patients with unresectable in-transit melanoma appear to have markedly decreased levels of immune activating cytokines compared to normal healthy controls. This further supports a potential role for immune-targeted therapies and immune monitoring in patients with regionally advanced melanoma.
Authors: Amanda K Raymond; Georgia M Beasley; Gloria Broadwater; Christina K Augustine; James C Padussis; Ryan Turley; Bercedis Peterson; Hilliard Seigler; Scott K Pruitt; Douglas S Tyler Journal: J Am Coll Surg Date: 2011-04-13 Impact factor: 6.113
Authors: Esther P M Tjin; Debby Konijnenberg; Gabrielle Krebbers; Henk Mallo; Jan W Drijfhout; Kees L M C Franken; Chantal M A M van der Horst; Jan D Bos; Omgo E Nieweg; Bin B R Kroon; John B A G Haanen; Cornelis J M Melief; Florry A Vyth-Dreese; Rosalie M Luiten Journal: Clin Cancer Res Date: 2011-07-12 Impact factor: 12.531
Authors: Georgia M Beasley; Jonathan C Riboh; Christina K Augustine; Jonathan S Zager; Steven N Hochwald; Stephen R Grobmyer; Bercedis Peterson; Richard Royal; Merrick I Ross; Douglas S Tyler Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo Journal: Cancer Res Date: 2010-06-15 Impact factor: 12.701
Authors: Marianna Sabatino; Seunghee Kim-Schulze; Monica C Panelli; David Stroncek; Ena Wang; Bret Taback; Dae Won Kim; Gail Deraffele; Zoltan Pos; Francesco M Marincola; Howard L Kaufman Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: Vinod P Balachandran; Michael J Cavnar; Shan Zeng; Zubin M Bamboat; Lee M Ocuin; Hebroon Obaid; Eric C Sorenson; Rachel Popow; Charlotte Ariyan; Ferdinand Rossi; Peter Besmer; Tianhua Guo; Cristina R Antonescu; Takahiro Taguchi; Jianda Yuan; Jedd D Wolchok; James P Allison; Ronald P DeMatteo Journal: Nat Med Date: 2011-08-28 Impact factor: 53.440
Authors: Georgia M Beasley; Paul Speicher; Christina K Augustine; Paul C Dolber; Bercedis L Peterson; Ketan Sharma; Paul J Mosca; Richard Royal; Merrick Ross; Jonathan S Zager; Douglas S Tyler Journal: Ann Surg Oncol Date: 2014-08-22 Impact factor: 5.344
Authors: Michael J Carr; James Sun; Hidde M Kroon; John T Miura; Georgia M Beasley; Norma E Farrow; Paul J Mosca; Michael C Lowe; Clara R Farley; Youngchul Kim; Syeda Mahrukh Hussnain Naqvi; Dennis A Kirichenko; Aishwarya Potdar; Hala Daou; Dean Mullen; Jeffrey M Farma; Michael A Henderson; David Speakman; Jonathan Serpell; Keith A Delman; B Mark Smithers; Brendon J Coventry; Douglas S Tyler; John F Thompson; Jonathan S Zager Journal: Ann Surg Oncol Date: 2020-09-11 Impact factor: 5.344
Authors: Betty S Jiang; Georgia M Beasley; Paul J Speicher; Paul J Mosca; Michael A Morse; Brent Hanks; April Salama; Douglas S Tyler Journal: Ann Surg Oncol Date: 2014-04-04 Impact factor: 5.344
Authors: Ahmad A Tarhini; Haris Zahoor; Yan Lin; Usha Malhotra; Cindy Sander; Lisa H Butterfield; John M Kirkwood Journal: J Immunother Cancer Date: 2015-09-15 Impact factor: 13.751